Company intelligence / Profile preview

Disproquima

Ownership: Private
Development stage: Other

Overview

Disproquima provides distribution and development of raw materials and premium ingredients across pharmaceuticals, dietary supplements, personal care, human nutrition, and animal nutrition sectors. The company recently expanded its portfolio by acquiring Res Pharma to strengthen its global presence in the life science industry.

Modalities: Small moleculeProtein
Industry: Chemicals & Materials

Partnerships

Collaborates with clients across pharma/dietary supplement/personal care/food & beverage/animal nutrition industries globallyNo specific major pharmaceutical or biotech partnerships listed.

Beyond the preview

Go deeper on Disproquima.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Disproquima.

Explore the full profile